Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin (SAIL)

This study has been terminated.
(Error made by local pharmacy caused mixed randomization of 20 participants)
Novo Nordisk A/S
Information provided by (Responsible Party):
Dr. Vincent Woo, University of Manitoba Identifier:
First received: June 21, 2012
Last updated: January 20, 2016
Last verified: January 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: November 2015
  Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)